Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Urethane SCHEMBL27632514 | 0.81 | ALOX15 (1.00) | ALOX15GAAMGAMSIMGAM2 | |
| Urethane SCHEMBL8505249 | 0.81 | ALOX15 (1.00) | ALOX15GAAMGAMSIMGAM2 | |
| Urethane SCHEMBL8136 | 0.81 | — | — | |
| Urethane SCHEMBL8830978 | 0.81 | ALOX15 (1.00) | ALOX15GAAMGAMSIMGAM2 | |
| Urethane SCHEMBL367439 | 0.81 | ALOX15 (1.00) | ALOX15GAAMGAMSIMGAM2 | |
| Urethane SCHEMBL8129017 | 0.81 | ALOX15 (1.00) | ALOX15GAAMGAMSIMGAM2 | |
| SCHEMBL27411503 | 0.79 | ALDH1A1 (0.63) | ALOX15GAAMGAMSIMGAM2 | |
| Urethane SCHEMBL6290773 | 0.78 | — | — | |
| Urethane SCHEMBL17556585 | 0.78 | — | — | |
| Urethane SCHEMBL4270027 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102697704-A | Controlled release formulations of opioid and nonopioid analgesics | ALZA CORP | 2012-10-03 | — | — | CN | claimed |
| CN-1662226-A | Monocompartment osmotic controlled drug delivery system | RANBAXY LAB LTD (IN) | 2005-08-31 | — | — | CN | claimed |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
| CN-103257189-B | (S)-MNTX, its synthetic method with and medicinal usage | PROGENICS PHARM INC. (US) | 2016-05-11 | — | — | CN | disclosed |
| EP-2755949-B1 | FUNGICIDAL 4-SUBSTITUTED-3-{PHENYL[(HETEROCYCLYLMETHOXY)IMINO]METHYL}-1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER IP GMBH (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-9090600-B2 | Fungicidal 4-substituted-3-{phenyl[(heterocyclylmethoxy)imino]methyl}-1,2,4-oxadizol-5(4H)-one derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| CN-104069088-A | Methods of treating gastrointestinal disorders independent of the intake of food | TAKEDA PHARMACEUTICALS NORTH AMERICA INC | 2014-10-01 | — | — | CN | disclosed |
| CN-103402499-A | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC | 2013-11-20 | — | — | CN | disclosed |
| CN-101208345-B | (S) -N-methylnaltrexone, method of synthesis and pharmaceutical use thereof | PROGENICS PHARM INC | 2013-10-16 | — | — | CN | disclosed |
| CN-1767830-A | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome | PROGENICS PHARM INC (US) | 2006-05-03 | — | — | CN | disclosed |
| CN-1767855-A | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist | PROGENICS PHARM INC (US) | 2006-05-03 | — | — | CN | disclosed |
| CN-1227003-C | Dosage form comprising liquid formulation | ALZA CORP (US) | 2005-11-16 | — | — | CN | disclosed |
| CN-1662226-A | Monocompartment osmotic controlled drug delivery system | RANBAXY LAB LTD (IN) | 2005-08-31 | — | — | CN | disclosed |
| US-20040220054-A1 | Recording material | FUJI PHOTO FILM CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1473591-A1 | Recording material | FUJI PHOTO FILM CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| CN-1406126-A | New sustained release oral formulations | NOVARTIS AG (CH) | 2003-03-26 | — | — | CN | disclosed |
| CN-1316897-A | Dosage form comprising liquid formulation | ALZA CORP (US) | 2001-10-10 | — | — | CN | disclosed |
| CN-1098286-A | The osmotic bursting delivery devices that pH causes | PFIZER (US) | 1995-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349848-A1 | FUNGICIDAL 4-SUBSTITUTED-3--1,2,4-OXADIZOL-5(4H)-ONE DERIVATIVES | CYP4X1, CYP4B1, CYP4Z1 | ALOX15 2823/4885GAA 1441/4885MGAM 1252/4885 |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | ALOX15 4421/4885GAA 1320/4885MGAM 1614/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | ALOX15 4383/4885GAA 1583/4885MGAM 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.